José I López

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7584402/publications.pdf

Version: 2024-02-01

217 papers 6,666 citations

39 h-index 91828

g-index

235 all docs

235 docs citations

times ranked

235

7245 citing authors

#	Article	IF	CITATIONS
1	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Modern Pathology, 2022, 35, 344-351.	2.9	40
2	Renal cell tumor with sex-cord/gonadoblastoma-like features: analysis of 6 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 349-358.	1.4	7
3	Urological Cancer Panorama in the Second Year of the COVID-19 Pandemic. Cancers, 2022, 14, 493.	1.7	1
4	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	3.4	30
5	Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level. Current Urology Reports, 2022, 23, 93-97.	1.0	7
6	Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas. Cancers, 2022, 14, 3381.	1.7	7
7	Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 667.	1.7	27
8	Mimickers of Urothelial Carcinoma and the Approach to Differential Diagnosis. Clinics and Practice, 2021, 11, 110-123.	0.6	5
9	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	2.9	118
10	Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours. Diagnostics, 2021, 11, 272.	1.3	7
11	A global analysis of the reconstitution of PTEN function by translational readthrough of <i>PTEN </i> pathogenic premature termination codons. Human Mutation, 2021, 42, 551-566.	1.1	7
12	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	2.9	138
13	The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. Cancers, 2021, 13, 2071.	1.7	25
14	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	3.4	50
15	SARS-CoV-2-Associated Obliterative Arteritis Causing Massive Testicular Infarction. Clinics and Practice, 2021, 11, 246-249.	0.6	3
16	Immune checkpoint B7â€H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Prostate, 2021, 81, 838-848.	1.2	13
17	Metastasis, an Example of Evolvability. Cancers, 2021, 13, 3653.	1.7	8
18	An Approach to Cell Motility as a Key Mechanism in Oncology. Cancers, 2021, 13, 3576.	1.7	0

#	Article	IF	Citations
19	Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). Cancers, 2021, 13, 4401.	1.7	8
20	Precision sampling fuels precision oncology: an evolutionary perspective. Trends in Cancer, 2021, 7, 978-981.	3.8	4
21	Insights into Urological Cancer. Cancers, 2021, 13, 204.	1.7	4
22	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	7.7	126
23	(Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder. Cancers, 2021, 13, 5642.	1.7	4
24	Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets. Frontiers in Cell and Developmental Biology, 2021, 9, 811297.	1.8	3
25	The role of cancer-associated fibroblasts in renal cell carcinoma. An example of tumor modulation through tumor/non-tumor cell interactions. Journal of Advanced Research, 2020, 21, 103-108.	4.4	40
26	Pre-implantation kidney biopsy: value of the expertise in determining histological score and comparison with the whole organ on a series of discarded kidneys. Journal of Nephrology, 2020, 33, 167-176.	0.9	34
27	Altered Tissue and Plasma Levels of Fibroblast Activation Protein- \hat{l}_{\pm} (FAP) in Renal Tumours. Cancers, 2020, 12, 3393.	1.7	17
28	Cell Motility and Cancer. Cancers, 2020, 12, 2177.	1.7	19
29	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. Journal of Experimental Medicine, 2020, 217, .	4.2	19
30	High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Research, 2020, 80, 4244-4257.	0.4	27
31	Unusual Faces of Bladder Cancers. Cancers, 2020, 12, 3706.	1.7	5
32	Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer. Journal of Personalized Medicine, 2020, 10, 265.	1.1	3
33	EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 300.	1.7	9
34	The Labyrinth of Renal Cell Carcinoma. Cancers, 2020, 12, 521.	1.7	10
35	The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. Cancers, 2020, 12, 513.	1.7	14
36	The role of protein tyrosine phosphatases in prostate cancer biology. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 102-113.	1.9	18

#	Article	IF	CITATIONS
37	Evidence of conditioned behavior in amoebae. Nature Communications, 2019, 10, 3690.	5.8	30
38	The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Human Pathology, 2019, 91, 61-68.	1.1	50
39	Common and uncommon features of nephrogenic adenoma revisited. Pathology Research and Practice, 2019, 215, 152561.	1.0	6
40	Precise Immunodetection of PTEN Protein in Human Neoplasia. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a036293.	2.9	11
41	Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology. Npj Precision Oncology, 2019, 3, 11.	2.3	15
42	Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation. International Journal of Molecular Sciences, 2019, 20, 1170.	1.8	11
43	Core-needle biopsy in thyroid nodules: performance, accuracy, and complications. European Radiology, 2019, 29, 4889-4896.	2.3	23
44	Sequential treatment of metastatic renal cancer in a complex evolving landscape. Annals of Translational Medicine, 2019, 7, S272-S272.	0.7	6
45	The nucleus does not significantly affect the migratory trajectories of amoeba in two-dimensional environments. Scientific Reports, 2019, 9, 16369.	1.6	7
46	A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 2019, 20, 1.	1.0	63
47	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell, 2018, 173, 611-623.e17.	13.5	398
48	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, 2018, 173, 595-610.e11.	13.5	472
49	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12.	13.5	609
50	High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma. Annals of Diagnostic Pathology, 2018, 34, 27-30.	0.6	8
51	Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 2018, 19, 3.	1.0	25
52	A pathogenic role for germline PTEN variants which accumulate into the nucleus. European Journal of Human Genetics, 2018, 26, 1180-1187.	1.4	21
53	Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma. Annals of Diagnostic Pathology, 2018, 34, 89-93.	0.6	11
54	Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. Journal of Molecular Diagnostics, 2018, 20, 34-45.	1.2	20

#	Article	IF	CITATIONS
55	Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 187-194.	1.4	10
56	Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. Histopathology, 2018, 72, 777-785.	1.6	31
57	The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling. Cancers, 2018, 10, 485.	1.7	9
58	"High-grade oncocytic renal tumor― morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 725-738.	1.4	83
59	DUSP5 expression associates with poor prognosis in human neuroblastoma. Experimental and Molecular Pathology, 2018, 105, 272-278.	0.9	10
60	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	2.1	22
61	Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. Pathology Research and Practice, 2018, 214, 1110-1114.	1.0	21
62	CD34 immunostaining enhances a distinct pattern of intratumor angiogenesis with prognostic implications in clear cell renal cell carcinoma. Apmis, 2017, 125, 128-133.	0.9	11
63	Multisite tumor sampling: a new tumor selection method to enhance intratumor heterogeneity detection. Human Pathology, 2017, 64, 1-6.	1.1	31
64	A <scp>DNA</scp> hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer. Apmis, 2017, 125, 787-796.	0.9	31
65	Transperineal biopsies of MRI-detected aggressive index lesions in low-Âand intermediate-risk prostate cancer patients: Implications for treatment decision. Brachytherapy, 2017, 16, 201-206.	0.2	3
66	Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma. BBA Clinical, 2017, 8, 97-102.	4.1	8
67	Cancer/testis antigen <scp>SPATA</scp> 19 is frequently expressed in benign prostatic hyperplasia and prostate cancer. Apmis, 2017, 125, 1092-1101.	0.9	6
68	Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC). American Journal of Surgical Pathology, 2017, 41, 1299-1308.	2.1	107
69	Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective. Frontiers in Medicine, 2017, 4, 25.	1.2	11
70	Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. PLoS ONE, 2017, 12, e0181711.	1.1	32
71	The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases. PLoS ONE, 2016, 11, e0169105.	1.1	43
72	Rheb/mTOR/p70s6k Cascade and TFE3 Expression in Conventional and Sclerosing PEComas of the Urinary Tract. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 514-520.	0.6	2

#	Article	IF	Citations
73	Biphasic Squamoid Alveolar Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 664-675.	2.1	48
74	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 60-71.	2.1	139
75	Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist. Apmis, 2016, 124, 153-159.	0.9	24
76	Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 69, 340-341.	1.6	3
77	Desvelando el proceso de producción de Les Tumeurs de la Vessie de JoaquÃn Albarrán 125 años después de su escritura. Actas Urológicas Españolas, 2016, 40, 463-469.	0.3	0
78	Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. Human Pathology, 2016, 54, 100-105.	1.1	43
79	A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy. Urologia Internationalis, 2016, 97, 16-25.	0.6	7
80	DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects. Molecular Diagnosis and Therapy, 2016, 20, 531-549.	1.6	4
81	Survival predictors in patients with prostate adenocarcinoma with hormonal blockade. Pathology Research and Practice, 2016, 212, 899-903.	1.0	3
82	Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 669-678.	1.4	20
83	Snail heterogeneity in clear cell renal cell carcinoma. BMC Cancer, 2016, 16, 194.	1.1	9
84	Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial. Radiotherapy and Oncology, 2016, 119, 91-96.	0.3	68
85	Study of breast cancer incidence in patients of lymphangioleiomyomatosis. Breast Cancer Research and Treatment, 2016, 156, 195-201.	1.1	9
86	Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile. Journal of Urology, 2016, 195, 619-626.	0.2	42
87	Assessing PTEN Subcellular Localization. Methods in Molecular Biology, 2016, 1388, 169-186.	0.4	9
88	Low-grade metastases in high-grade clear cell renal cell carcinomas. Annals of Diagnostic Pathology, 2016, 20, 13-18.	0.6	4
89	Ultrasound-guided core-needle biopsy in thyroid nodules. A study of 676 consecutive cases with surgical correlation. European Radiology, 2016, 26, 1-8.	2.3	63
90	A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma. F1000Research, 2016, 5, 385.	0.8	22

#	Article	IF	Citations
91	A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma. F1000Research, 2016, 5, 385.	0.8	16
92	Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma. F1000Research, 2016, 5, 607.	0.8	8
93	Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma. F1000Research, 2016, 5, 607.	0.8	3
94	A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling. F1000Research, 2016, 5, 1587.	0.8	8
95	A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling. F1000Research, 2016, 5, 1587.	0.8	7
96	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). F1000Research, 2016, 5, 2020.	0.8	11
97	Aminopeptidase N Activity Predicts 5-Year Survival in Colorectal Cancer Patients. Journal of Investigative Medicine, 2015, 63, 740-746.	0.7	24
98	Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects. Polish Journal of Pathology, 2015, 1, 3-8.	0.1	16
99	Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. PLoS ONE, 2015, 10, e0132546.	1.1	15
100	Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer. International Journal of Medical Sciences, 2015, 12, 458-467.	1.1	5
101	The normal and pathologic renal medulla: A comprehensive overview. Pathology Research and Practice, 2015, 211, 271-280.	1.0	8
102	Large (>3.8Âcm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 61-66.	1.4	18
103	Chromophobe renal cell carcinoma with neuroendocrine and neuroendocrine-like features. Morphologic, immunohistochemical, ultrastructural, and array comparative genomic hybridization analysis of 18 cases and review of the literature. Annals of Diagnostic Pathology, 2015, 19, 261-268.	0.6	26
104	Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis. PLoS ONE, 2015, 10, e0119436.	1.1	28
105	Prolyl Endopeptidase Activity Is Correlated with Colorectal Cancer Prognosis. International Journal of Medical Sciences, 2014, 11, 199-208.	1.1	20
106	Utilidad diagn \tilde{A}^3 stica del estudio citol \tilde{A}^3 gico del tamp \tilde{A}^3 n de transporte en biopsias por punci \tilde{A}^3 n prost \tilde{A}_1 tica transrectal. Actas Urol \tilde{A}^3 gicas Espa \tilde{A} ±olas, 2014, 38, 566-570.	0.3	0
107	Targeted nextâ€generation sequencing and nonâ€coding <scp>RNA</scp> expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. Journal of Pathology, 2014, 232, 32-42.	2.1	51
108	Genes reparadores del ADN y pronóstico en formas esporádicas de carcinoma urotelial del tracto urinario superior. Actas Urológicas Españolas, 2014, 38, 600-607.	0.3	11

#	Article	IF	Citations
109	DNA repair genes and prognosis in sporadic forms of urothelial carcinoma of the upper urinary tract. Actas $UrolA^3$ gicas Espa $A\pm olas$ (English Edition), 2014, 38, 600-607.	0.2	11
110	Diagnostic usefulness of the cytological study of the transport buffer in transrectal prostate core biopsies. Actas Urológicas Españolas (English Edition), 2014, 38, 566-570.	0.2	0
111	Prostate anatomy in motheaten viable (mev) mice with mutations in the protein tyrosine phosphatase SHP-1. Actas Urológicas Españolas (English Edition), 2014, 38, 438-444.	0.2	1
112	A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate, 2014, 74, 1171-1182.	1.2	58
113	Altered glutamyl-aminopeptidase activity and expression in renal neoplasms. BMC Cancer, 2014, 14, 386.	1.1	7
114	AnatomÃa de la próstata en ratones motheaten viable (mev) con mutaciones en el gen de la proteÃna tirosina fosfatasa SHP-1. Actas Urológicas Españolas, 2014, 38, 438-444.	0.3	1
115	Impacto de la expresión de p53, MIB-1 y PECAM-1 en el pronóstico del carcinoma urotelial de la pelvis renal. Actas Urológicas Españolas, 2014, 38, 506-514.	0.3	10
116	Clear cell papillary renal cell carcinoma: a review. International Journal of Clinical and Experimental Pathology, 2014, 7, 7312-8.	0.5	24
117	Clinical impact of aspartyl aminopeptidase expression and activity in colorectal cancer. Translational Research, 2013, 162, 297-308.	2.2	11
118	Nephrogenic adenoma of the urinary tract: clinical, histological, and immunohistochemical characteristics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 819-825.	1.4	26
119	Cannabinoid CB1 receptor is expressed in chromophobe renal cell carcinoma and renal oncocytoma. Clinical Biochemistry, 2013, 46, 638-641.	0.8	12
120	Renal tumors with clear cells. A review. Pathology Research and Practice, 2013, 209, 137-146.	1.0	50
121	Altered Peptidase Activities in Thyroid Neoplasia and Hyperplasia. Disease Markers, 2013, 35, 825-832.	0.6	10
122	Cell heterogeneity in clear cell renal cell carcinoma. Apmis, 2013, 121, 1187-1191.	0.9	16
123	The ejaculatory ducts and their implications in prostate adenocarcinoma. Analytical and Quantitative Cytopathology and Histopathology, 2013, 35, 205-9.	0.2	0
124	The impact of peptidase activity on clear cell renal cell carcinoma survival. American Journal of Physiology - Renal Physiology, 2012, 303, F1584-F1591.	1.3	37
125	Histological Diagnosis of Thyroid Disease Using Ultrasound-Guided Core Biopsies. European Thyroid Journal, 2012, 2, 29-36.	1.2	13
126	Collision tumour involving a rectal gastrointestinal stromal tumour with invasion of the prostate and a prostatic adenocarcinoma. Diagnostic Pathology, 2012, 7, 150.	0.9	14

#	Article	IF	CITATIONS
127	Giant cell ependymoma-report of three cases and review of the literature. International Journal of Clinical and Experimental Pathology, 2012, 5, 458-62.	0.5	12
128	Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regulatory Peptides, 2010, 165, 218-223.	1.9	21
129	Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer, 2010, 10, 193.	1.1	40
130	Re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pTO in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? Eur Urol 2009;56:272–4. European Urology, 2010, 57, e21.	0.9	2
131	Cannabinoid CB ₁ Receptor Is Downregulated in Clear Cell Renal Cell Carcinoma. Journal of Histochemistry and Cytochemistry, 2010, 58, 1129-1134.	1.3	27
132	Renal Cell Carcinoma in Young Adults: A Study of 130 Cases and a Review of Previous Series. Urologia Internationalis, 2010, 84, 292-300.	0.6	13
133	Increased prolyl endopeptidase activity in human neoplasia. Regulatory Peptides, 2010, 163, 102-106.	1.9	31
134	Expression of cannabinoid receptors in human kidney. Histology and Histopathology, 2010, 25, 1133-8.	0.5	42
135	Concurrent solitary fibrous tumor and low-grade fibrillary astrocytoma of the cerebellum. , 2010, 29, 301-306.		3
136	Changes in cell-surface peptidase activity in papillary renal cell carcinoma. Anticancer Research, 2010, 30, 1137-41.	0.5	7
137	Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance. International Urology and Nephrology, 2009, 41, 847-854.	0.6	6
138	Fraction of positive cores in prostate needle biopsy is significantly predictive of pathological stage in radical prostatectomy. Histopathology, 2009, 54, 374-375.	1.6	0
139	El diagnóstico histológico de la patologÃa tiroidea en biopsias guiadas por control ecográfico. Revista Espanola De Patologia, 2009, 42, 97-106.	0.6	6
140	Clinicopathological Study of Regressed Testicular Tumors (Apparent Extragonadal Germ Cell) Tj ETQq0 0 0 rgBT /	/Overlock	10 ₅ tf 50 222
141	Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification. American Journal of Surgical Pathology, 2009, 33, 1840-1849.	2.1	121
142	Renal Angiomyolipoma. American Journal of Surgical Pathology, 2009, 33, 289-297.	2.1	216
143	Basaloid Squamous Cell Carcinoma of the Head and Neck. Head and Neck Pathology, 2008, 2, 83-91.	1.3	86
144	Prostatic remnants in mature cystic teratoma of the ovary. Annals of Diagnostic Pathology, 2008, 12, 378-380.	0.6	11

#	Article	IF	Citations
145	Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. American Journal of Physiology - Renal Physiology, 2008, 294, F850-F858.	1.3	15
146	Histopathology of Diaphragm Disease of the Small Intestine. American Journal of Clinical Pathology, 2008, 130, 518-525.	0.4	48
147	Middle-ear carcinoid tumor with distant metastasis and fatal outcome. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 53-56.	0.6	13
148	Sclerosing mucoepidermoid carcinoma of the thyroid gland: cytohistological findings of a case. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 62-65.	0.6	6
149	Tubulocystic Carcinoma of the Kidney. American Journal of Surgical Pathology, 2008, 32, 177-187.	2.1	156
150	Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. American Journal of Physiology - Renal Physiology, 2007, 292, F780-F788.	1.3	43
151	Giant cell ependymoma: two new cases and review of the literature. Journal of Neuropathology and Experimental Neurology, 2007, 66, 445.	0.9	0
152	Cystinyl aminopeptidase activity is decreased in renal cell carcinomas. Regulatory Peptides, 2007, 144, 56-61.	1.9	10
153	Adult-Type Granulosa Cell Tumor of the Testis. Report of a Case. Tumori, 2007, 93, 223-224.	0.6	14
154	Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma. Journal of Clinical Ultrasound, 2007, 35, 295-301.	0.4	52
155	Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation. BJU International, 2007, 100, 1272-1276.	1.3	22
156	Expresión de pRb, p53 y bcl-2 en el carcinoma de células transicionales de bajo grado no infiltrante (pTa) de la vejiga urinaria. Revista Espanola De Patologia, 2006, 39, 149-154.	0.6	0
157	Role of ultrasound-guided core biopsy in the evaluation of spleen pathology. Apmis, 2006, 114, 492-499.	0.9	33
158	Orbital giant cell angiofibroma Apmis, 2006, 114, 663-665.	0.9	26
159	The combination of millimetres of cancer and Gleason index in core biopsy is a predictor of extraprostatic disease. Histopathology, 2006, 48, 663-667.	1.6	19
160	Temporal bone secretory meningioma presenting as a middle ear mass. Pathology Research and Practice, 2006, 202, 481-484.	1.0	8
161	Renal mucinous and tubular spindle cell carcinoma: a clinicopathological study of 4 cases. Annals of Saudi Medicine, 2006, 26, 466-470.	0.5	7
162	The biphasic pattern of laryngeal and hypopharyngeal adenosquamous carcinoma is retained in lymph node metastases. Histopathology, 2005, 46, 715-716.	1.6	8

#	ARTICLE	IF	CITATIONS
163	Primary sinonasal ameloblastoma. Case report. Apmis, 2005, 113, 148-150.	0.9	17
164	Usefulness and limitations of ultrasound-guided core biopsy in the diagnosis of musculoskeletal tumours. Apmis, 2005, 113, 353-360.	0.9	40
165	Malakoplakia associated with colorectal adenocarcinoma. Annals of Saudi Medicine, 2005, 25, 50-52.	0.5	2
166	Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 915-926.	1.8	65
167	Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 915-926.	1.8	17
168	Papillary squamous cell carcinoma of the larynx. Journal of Laryngology and Otology, 2001, 115, 164-166.	0.4	19
169	Verrucous Carcinoma of the Esophagus. Endoscopy, 2001, 33, 297-297.	1.0	8
170	Plasmacytoid Myoepithelioma of the Soft Palate. Acta Cytologica, 2000, 44, 647-652.	0.7	16
171	Micropapillary transitional cell carcinoma of the urinary bladder. Histopathology, 1999, 34, 561-562.	1.6	20
172	Breast Carcinoma with Endocrine Features. Acta Cytologica, 1998, 42, 1017-1021.	0.7	5
173	Atypical carcinoid of larynx: presentation with scalp metastases. Journal of Laryngology and Otology, 1997, 111, 89-91.	0.4	20
174	RE: THE IMPORTANCE OF THE DEPTH OF INVASION IN STAGE T1 BLADDER CARCINOMA: A PROSPECTIVE COHORT STUDY. Journal of Urology, 1997, 158, 1922-1922.	0.2	8
175	Malignant Fibrous Histiocytoma of the Renal Capsule and Synchronous Transitional Cell Carcinoma of the Bladder. Pathology Research and Practice, 1996, 192, 468-471.	1.0	8
176	Primary Cisplatin, Methotrexate and Vinblastine Aiming at Bladder Preservation in Invasive Bladder Cancer: Multivariate Analysis on Prognostic Factors. Journal of Urology, 1996, 155, 1897-1902.	0.2	42
177	Outcome of silent lupus nephritis. Seminars in Arthritis and Rheumatism, 1996, 26, 468-476.	1.6	60
178	Report of a case with immunohistochemical study. Apmis, 1996, 104, 99-102.	0.9	19
179	Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis and Rheumatism, 1996, 39, 2028-2034.	6.7	89
180	The prognostic significance of vascular invasion in stage T1 bladder cancer. Histopathology, 1995, 27, 27-33.	1.6	56

#	Article	IF	CITATIONS
181	Mucinous (colloid) adenocarcinoma of the prostate. British Journal of Urology, 1995, 76, 805-806.	0.1	4
182	Combined Therapy in a Case of Malignant Mesothelioma of the Tunica Vaginalis Testis. Scandinavian Journal of Urology and Nephrology, 1995, 29, 361-364.	1.4	12
183	Muscularis mucosa differentiates two populations with different prognosis in Stage T1 bladder cancer. Urology, 1995, 45, 47-53.	0.5	134
184	In Reply: Re Pseudosarcomatous Myofibroblastic Proliferation of the Bladder Report of 2 Cases and Literature Review. Journal of Urology, 1995, 154, 537-537.	0.2	0
185	Burned-out tumour of the testis presenting as retroperitoneal choriocarcinoma. International Urology and Nephrology, 1994, 26, 549-553.	0.6	35
186	Carcinosarcoma of the parotid gland Histopathology, 1994, 25, 388-390.	1.6	10
187	Small cell carcinoma of the urinary bladder. A clinicopathological study of six cases. British Journal of Urology, 1994, 73, 43-49.	0.1	63
188	Expression of keratin 20 in malignant eccrine poromas. Pathology Research and Practice, 1994, 190, 11-14.	1.0	2
189	Phyllodes Tumor of the Breast. Pathology Research and Practice, 1994, 190, 474-481.	1.0	34
190	Lethal Cytomegalovirus Adrenalitis in a Case of Aids. Scandinavian Journal of Urology and Nephrology, 1994, 28, 105-106.	1.4	8
191	Extrarenal Retroperitoneal Angiomyolipoma. Urologia Internationalis, 1994, 52, 58-60.	0.6	25
192	Pseudosarcomatous Myofibroblastic Proliferation of the Bladder: Report of 2 Cases and Literature Review. Journal of Urology, 1994, 151, 1008-1012.	0.2	34
193	Fine-needle aspiration cytology of a membranous basal cell adenoma arising in an intraparotid lymph node. Diagnostic Cytopathology, 1993, 9, 668-672.	0.5	13
194	ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA OF THE LOWER LIP. International Journal of Dermatology, 1993, 32, 361-362.	0.5	12
195	A case of Whipple's disease presenting as supraclavicular lymphadenopathy. Apmis, 1993, 101, 865-868.	0.9	13
196	The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification. Journal of Cancer Research and Clinical Oncology, 1993, 119, 578-593.	1.2	31
197	Central Mucoepidermoid Carcinoma. Pathology Research and Practice, 1993, 189, 365-367.	1.0	10
198	Primary Malignant Melanoma Mimicking Urethral Caruncle. Scandinavian Journal of Urology and Nephrology, 1993, 27, 125-126.	1.4	20

#	Article	lF	Citations
199	Cavitation of Lung Metastases from Bladder Cancer. Report of two Cases. Tumori, 1993, 79, 141-143.	0.6	5
200	Pigmented Dermatofibrosarcoma protuberans (Bednar Tumour). Dermatology, 1992, 184, 281-282.	0.9	5
201	Intrathoracic Kidney and Vertebral Fusion: A Model of Combined Misdevelopment. Journal of Urology, 1992, 147, 1351-1353.	0.2	21
202	Rhabdomyoma of the vagina. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 45, 147-148.	0.5	8
203	Kaposi's Sarcoma of the Penis as an Initial Urological Manifestation of AIDS. Urologia Internationalis, 1991, 46, 235-237.	0.6	39
204	Pleomorphic adenoma of the breast. Apmis, 1991, 99, 866-868.	0.9	9
205	Congenital mesoblastic nephroma, nephrocalcinosis, and hypertrophic pyloric stenosis. Journal of Surgical Oncology, 1991, 48, 142-144.	0.8	3
206	Undifferentiated carcinoma of parotid gland Journal of Clinical Pathology, 1991, 44, 432-433.	1.0	4
207	Metastasising Carcinoma of the Urinary Bladder Presenting as a Retro-Orbital Mass. Scandinavian Journal of Urology and Nephrology, 1991, 25, 83-84.	1.4	19
208	Pharyngeal adenocarcinoma with intestinal features. Journal of Laryngology and Otology, 1990, 104, 900-902.	0.4	4
209	Inflammatory pseudotumor of the liver. Apmis, 1990, 98, 1022-1026.	0.9	11
210	Intestinal-Type Adenocarcinoma of the Nasal Cavity and Paranasal Sinuses. A Clinicopathologic Study of 6 Cases. Tumori, 1990, 76, 250-254.	0.6	20
211	Absence of Estrogen Immunoreactivity in Adenomatoid Tumors of Male Reproductive System. Pathology Research and Practice, 1990, 186, 395-396.	1.0	0
212	Pulmonary Hypertension Due to Toxic Oil Syndrome. Chest, 1989, 95, 325-331.	0.4	70
213	Hemophagocytic Syndrome Causing Complete Bone Marrow Failure. Acta Haematologica, 1989, 82, 197-200.	0.7	4
214	Pseudomelanosis of the Duodenum. Journal of Clinical Gastroenterology, 1988, 10, 150-154.	1.1	17
215	Grade heterogeneity in clear cell renal cell carcinoma. Bjui, 0, , .	0.0	6
216	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). F1000Research, 0, 5, 2020.	0.8	6

#	Article	lF	CITATIONS
217	Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer. Frontiers in Oncology, 0, 12 , .	1.3	9